Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Comparison of Two Graft Choices in Mediale Patellofemoral Ligament Reconstruction (MPFL)

NCT05706363 · tracked via the Priya Life Science Denmark tracker
Phase
Not applicable
Started
2017-07-01
Last updated
2025-10-03

Condition(s) studied

Patellar Dislocation

Investigational drug(s) / intervention(s)

Quadriceps graft

Quadriceps graft: Using quadriceps graft as new medial patellofemoral ligament graft. Fixated with suture anchor

Study summary

The purpose of this study is to elucidate surgical techniques for reconstructing MPFL in the treatment of chronic patella instability. The two techniques are conventional technique with the gracillis and screw fixation in the femur which is compared with new technique where the QT tendons and anchor fixation in the femur are used.

It would be investigated which technique provides the best stability with the least postoperative pain from the reconstruction and the lowest frequency of patellar reluxation.

Eligibility

Sex
ALL
Min age
15 Years
Max age
40 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Patients between 15 and 40 years of age with chronic tendency to lateral patellar dislocation (defined as 2 or more verified dislocation cases) * The growth zones must be found closed - verified by MRI scan Exclusion Criteria: * Patients with known rheumatoid arthritis. * Patients with arthroscopically detected osteoarthritis (grade 3 cartilage lesion) * Inability to follow a normal rehabilitation regime. * Previous ligament surgery in injured knees.

Primary outcome measure(s)

  • Kujala (Anterior Knee Pain Scale) — 24 month
    Patient reported outcome score, 0=worst and 100=best

Trial sites (1)

FacilityCityRegionStatus
Division of Sports Trauma, Palle Juul-Jensens Boulevard 99 Aarhus N Denmark
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05706363 on ClinicalTrials.gov ↗ ← All trials in Denmark